Cancer Be Gone..



Cancer Be Gone

The Patented Anti-Cancer Therapy Breakthrough that is entirely for and about the patient.

By Brenda Laster, Ph.D.

The Situation in Overview

Current Conventional Cancer Treatment Limitations and Drawbacks

Chemotherapy is a long and drawn out process. Drug delivery in chemotherapy is by systemic injection or oral ingestion, which is uncomfortable at best and extremely painful at worst. Patients suffer from tissue damage both during and after the chemotherapy procedure, which is normal but which can be extremely disheartening to the patient.  The patient’s liver and kidneys filter out and remove significant amounts of the original quantity of the drug administered, which reduces the actual effective dosage delivered to the target area and which makes the entire treatment process fraught with guesswork. The dosage that can and does reach the tumor itself is made to be even more of a mystery since the patient’s normal tissue tolerance is an unknown variable. The length of time chemotherapy takes is exacerbated by the high level of discomfort it causes in the patient, which makes it seem to take even longer than it does.

Surgery is frightening, over-the-top expensive, problematic in that we never can be certain we “got it all” and, when you factor it the pain that the patient must experience and the high risks one faces when infection is such a great possibility, surgery, as a mode of treatment, becomes less and less attractive.

Radiotherapy may appear to be a better option at first blush but the profound damage it causes to normal healthy tissues and organs within the targeted field makes the choice a truly frightening one. Plus, the radiotherapy option promises a very lengthy treatment period, which is also tremendously off-putting.

The one thing common to all three currently available anti-cancer treatments; Chemotherapy, Surgery and Radiotherapy, is the existance of tremendously adverse or negative side effects.

If only there was another way without these downside inevitabilities.

Well, now there is.

And, this new anti-cancer therapy is not only advantageous to patients who are hoping to avoid the painful and protracted experiences associated with the treatments of yesterday, but this new treatment offers attractive advantages to the pharma-related organizations that choose to offer it. Advantages include:

1. Production costs associated with this new anti-cancer treatment method are extremely low.

2. The potential for success are enormous due to the vast world-wide market waiting to be served.

3. The anticipated costs related to packaging, distribution and sales are extremely low.

4. The profit margins are projected to be extremely high.

5. This new therapy is already patent protected insuring a sole source position of what is almost destined to become a "must have" product.

The Treatment Details of our New Anti-Cancer Treatment are as follows:

FDA approved polymer solidified into a 3 mm x 1.5 mm (abount 1/8" x 1/16") rod and mixed with an anti-cancer drug.
Rod implanted directly into a solid tumor via seeding needle.
Drug continuously released from rod during its 30 day degradation.
Drug specifically targets tumor-promoting genetic structures in DNA and suppresses their expression.
Drug suppresses upregulation and amplification of genes and oncogenes that activate telomerace.
The Result is inhibition of telomerace enzyme preventing cancer cell immortality.
Tumor growth rate severally reduced.

Scientific Basis of Out Treatment.

All cells express genes the proteins of which activate growth pathways.
In cancer cells, these genes are over expressed and mutated.
Genetic areas in the tumor cell DNA form g-quadraplex (GQ) structures.
Our drug specifically targets GQ structures and its binding to the GQ silences cancer gene expression.

The drug  prevents over expression of tumor growth promoting genes.
Its long-term presence in a tumor prevents re-expression, amplification and upregulation of cancer genes that activate cancer cell survival pathways.

Advantages to Patient

Out-patient treatment; i.e. no hospital stay.
Minimal side-effects.
Single application of drug lasts 30 days.
Few medical visits.
Quality of life maintained.


Patent Details

Continuous Long-Term Controlled Release of Telomerase Inhibitors.

US Patent Number: US10188601B2

Inventor: Brenda Laster


Direct implantation of rod into tumor.
Prolonged presence of drug in tumor.
Tumor growth promoting genes suppressed.
Drug continuously available for newly dividing cells.
Ease of treatment application.
Drug does not enter blood stream.
Normal tissue not damaged.
Minimal side effects.
Patient’s quality of life preserved.
Patient spared rigors of conventional treatments.

Global Perspective

Global Cancer Medical Costs:
“Global spending on cancer medicines rose to $133 billion in 2017; up from $96 billion in 2013.”


Status of Our New Anti-Cancer Treatment

Completion of preclinical studies in 45 mice with the rod implanted in an aggressive murine mammary adenocarcinoma reduced the growth rate by a factor of 5 compared to 48 untreated controls. The p-value of the study was 0.0001.
Measurements of blood serum in these mice, over time, were minimal.

Next Steps

FDA Approval and Human Clinical Trials.

Interested parties who wish to make this new and important product to the medical community world-wide are invited to contact Dr. Brenda Laster through her representative at:

Geoffrey Drew Marketing, Inc.
740 West End Avenue; Suite 1
New York, NY 10025 USA

International Phone: (646)998-4208
International Fax: (646)998-4073
Toll-Free Phone: (800)839-2929
Toll-Free Fax: (888)329-6287


is produced by Geoffrey Drew Marketing, Inc.

© 2019 Geoffrey Drew Marketing, Inc.
All Rights Reserved. Reproduction Prohibited.
Please Note: It is prohibited to use any text or graphics in this web site without the written permission of

Geoffrey Drew Marketing, Inc.
Website by: Geoffrey Drew Marketing, Inc.
Hosted by: WestHost

Call Anytime:
Phone: (516)501-0744
Fax: (516)501-0753

Contact Us

Home Page